 NEW YORK--BUSINESS WIRE--Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Pandion Therapeutics, Inc. NASDAQ: PAND to Merck is fair to Pandion shareholders. Under the terms of the agreement, Pandion shareholders will receive 60.00 per share in cash. Halper Sadeh encourages Pandion shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at 212 763-0060 or or zhalpe 